Haywood Securities’ June 13 report argues that HealWELL AI is well-positioned to capitalize on its rapid growth ...

New diagnostic tools detect diseases at earlier stages while helping doctors personalize treatments. Medical institutions support these breakthrough tests through rigorous clinical trials and ...

The potential therapy for idiopathic pulmonary fibrosis is notable because not only was the small molecule discovered by ...

There are subtle but significant differences in the morphology and biochemistry of the eye between men and women. These differences may affect disease susceptibility, symptoms and progression, ...

Insulin resistance (IR) is a crucial factor in metabolic disorders like non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS), ...

Scientists from the A*STAR Genome Institute of Singapore (A*STAR GIS) have developed a new artificial intelligence (AI)-based ...

AI guidance for clinicians aimed at reducing the spread of Clostridioides difficile—a bacteria that can be deadly for sick ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

Recent studies assessed artificial intelligence (AI) assistance tools in their ability to provide quality medical recommendations for patients.

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

The technology’s potential to transform trials will need to be balanced with the challenge of instilling trust in participants.